Literature DB >> 17044784

Antigen-based immunofluorescence analysis of B-cell targeting: advanced technology for the generation of novel monoclonal antibodies with high efficiency and selectivity.

Masahiro Tomita1, Takatomi Fukuda, Akira Ozu, Kei-ichi Kimura, Tian Yow Tsong, Tetsuro Yoshimura.   

Abstract

On the basis of immunofluorescence analysis, an entire pathway of B-cell targeting was successfully identified, which can drive selective production of monoclonal antibodies with high efficiency and selectivity. The technique comprises three critical steps, antigen-based preselection of B lymphocytes, formation of antigenselected B lymphocyte and myeloma cell complexes, and selective fusion of B-cell-myeloma cell complexes with electrical pulses. Intriguingly, expression of surface immunoglobulin receptors on B lymphocytes was recognized even after immunization in vitro. The number of the antigen-selected B lymphocytes after in vitro immunization was in fact higher than that obtained after in vivo immunization, suggesting that such shortterm immunization is applicable for B-cell targeting. Immunofluorescence analysis revealed the targeting technique to demonstrate fivefold to tenfold higher efficiency for formation of hybridoma cells than a polyethylene glycol (PEG)-mediated method. This efficiency is in good agreement with production of hybridoma cells secreting desired monoclonal antibodies determined by an enzyme-linked immunosorbent assay (ELISA). The addition of a low concentration of PEG brought about enhanced fusion efficiency and reduced cell damage at even electric intensities as high as 4.0 kV/cm and 5.0 kV/cm. Here we demonstrate that immunofluorescence analysis can successfully clarify an entire pathway of B-cell targeting and provide advantages over the PEG-mediated method. This advanced technology may be applicable for rapid production of monoclonal antibodies based on in vitro immunization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17044784     DOI: 10.1089/hyb.2006.25.283

Source DB:  PubMed          Journal:  Hybridoma (Larchmt)        ISSN: 1554-0014


  1 in total

Review 1.  Hybridoma technology: is it still useful?

Authors:  Jane Zveiter Moraes; Bárbara Hamaguchi; Camila Braggion; Enzo Reina Speciale; Fernanda Beatriz Viana Cesar; Gabriela de Fátima da Silva Soares; Juliana Harumi Osaki; Tauane Mathias Pereira; Rodrigo Barbosa Aguiar
Journal:  Curr Res Immunol       Date:  2021-03-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.